Nautilus Biotechnology, Inc., a life sciences company based in Seattle, Washington, is making significant strides in the field of proteomics, aiming to transform biomedical research and drug discovery. As a Nasdaq-listed entity, Nautilus Biotechnology operates within the Health Care sector, focusing on leveraging cutting-edge technology to benefit patients and healthcare professionals worldwide.
As of October 29, 2026, the company’s stock closed at $2.73. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of $4.31 on March 24, 2026, and a low of $0.841 on August 6, 2026. Despite these variations, Nautilus Biotechnology maintains a market capitalization of approximately $399.95 million.
The company’s financial metrics reveal a Price Earnings (P/E) ratio of -5.89, indicating that it is currently not generating net income. This is not uncommon for companies in the biotechnology sector, where significant investments in research and development often precede profitability.
Nautilus Biotechnology’s mission is to revolutionize biomedical research and drug discovery through its specialized focus on proteomics. By advancing this field, the company aims to provide innovative solutions that can significantly impact patient care and healthcare outcomes globally. For more information about their work and offerings, interested parties can visit their website at www.nautilus.bio .
As Nautilus Biotechnology continues to develop its technologies and expand its influence in the life sciences sector, it remains committed to its goal of enhancing the capabilities of biomedical research and drug discovery, ultimately aiming to improve healthcare on a global scale.
